Ronald Maas is Director of CMC at AdJane. He has a background in microbiology and holds a PhD in bioprocess technology from Wageningen University. He has twenty-five years of experience in the development and scale-up of biotechnological processes and has built extensive expertise in the biopharmaceutical sector through various scientific and leadership roles, including at Merck Sharp & Dohme (MSD). At Intravacc, Ronald spent ten years in vaccine bioprocess development, covering the entire process up to the production of clinical trial material, with a focus on bacterial fermentation and the purification of outer membrane vesicles (OMVs).